Revenue
2019
2020
2021
2022
2023
2024
2025
RECURSION PHARMACEUTICALS, INC. (RXRX)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $74.7M | $58.8M | $44.6M | $39.8M | $10.2M | $4.0M | $2.3M |
| Research & development | $475.3M | $314.4M | $241.2M | $155.7M | $135.3M | $63.3M | $45.8M |
| Operating expenses | — | — | — | — | $193.0M | $88.6M | $64.8M |
| Operating income | −$648.1M | −$479.0M | −$350.1M | −$245.7M | −$182.8M | −$84.6M | −$62.4M |
| EBITDAderived | −$564.4M | −$442.5M | −$325.7M | −$234.0M | −$174.4M | −$80.7M | −$60.0M |
| Net income | −$644.8M | −$463.7M | −$328.1M | −$239.5M | −$186.5M | −$87.0M | −$61.9M |
| Basic EPSper diluted share | -$1.44 | -$1.69 | -$1.58 | -$1.36 | -$1.49 | -$3.99 | -$2.87 |
| Diluted EPSper diluted share | -$1.44 | -$1.69 | -$1.58 | -$1.36 | -$1.49 | -$3.99 | -$2.87 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 18, 2026Form 4 · 10b5-1 | Bumpus NamandjeDirector | SellClass A Common Stock | 4.0K | $3.18 | $12.6K | 127.6K |
| Jun 5, 2026Form 4 · 10b5-1 | Khan NajatCEO and President | SellClass A Common Stock | 23.6K | $3.58 | $84.4K | 2.18M |
| Jun 5, 2026Form 4 · 10b5-1 | Gibson ChristopherDirector | SellClass A Common Stock | 40.0K | $3.62 | $144.8K | 883.7K |
| Jun 3, 2026Form 4 · 10b5-1 | Bumpus NamandjeDirector | SellClass A Common Stock | 4.4K | $3.54 | $15.5K | 43.2K |
| Jun 2, 2026Form 4 · 10b5-1 | Borgeson BlakeDirector | SellClass A Common Stock | 30.0K | $3.68 | $110.4K | 6.17M |